Private equity committed USD90 billion to global healthcare deals in 2022 according to Bain & Company’s 12^th annual report on M&A activity. This significant capital injection – the second highest on record – shows that despite rising rates and market volatility last year, the global healthcare space is very much alive and kicking; and a further reminder of its recession-proof attributes. Rising labour costs and tighter credit conditions will require investors to perform a careful diagnosis this year, and consider creative approaches to deal making. Still, the long-term M&A outlook is likely to remain in rude health, especially in biopharma and life sciences.